Viatris Inc.

Viatris Inc.

VTRS

$18.67

Updated: 03/11/2026, 04:06:26

Market Cap
$21.44B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US

No historical data available

Company Profile

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

USD
NASDAQ
CEO: Scott Andrew Smith
Employees: 30,000
https://www.viatris.com
Asset Summaries
Latest generated summaries for VTRS

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
VTRS-10-k-fy2025.html3.7 MBtext/htmlENFiled 26/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 57 KPI observations

Revenue

$14.3B

FY 2025 · Reported

Net income

$-3.5B

FY 2025 · Reported

Gross margin

34.8%

FY 2025 · Calculated

Free cash flow

$1.9B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$0.5B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Portfolio composition

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Global healthcare company supplying medicines to ~1 billion patients annually; operations in 165+ countries, 30,000+ employees, 1,400+ approved molecules, 27 sites

98%
Source evidence
“The Company operates in more than 165 countries and territories with more than 30,000 employees. The Company has 27 manufacturing, packaging, and distribution sites worldwide, more than 1,400 approved molecules”

Company scale and footprint

Global healthcare company supplying medicines to ~1 billion patients/year; >165 countries and territories; >30,000 employees; 27 manufacturing/packaging/distribution sites; >1,400 approved molecules; global centers in Pittsburgh, Shanghai, Hyderabad

95%
Source evidence
“The Company operates in more than 165 countries and territories with more than 30,000 employees. The Company has 27 manufacturing, packaging, and distribution sites worldwide, more than 1,400 approved molecules”

Four reportable segments

Four reportable segments: Developed Markets, Greater China, JANZ, Emerging Markets, reported on the basis of markets and geography

98%
Source evidence
“Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography”

Four reportable segments

Developed Markets, Emerging Markets, JANZ, and Greater China across more than 165 countries and territories

97%
Source evidence
“Viatris provides unique reach through four segments – Developed Markets, Emerging Markets, JANZ, and Greater China – across more than 165 countries and territories.”

Emerging Markets segment

Emerging Markets: presence in more than 125 developing/emerging countries plus ARV franchise; products include Lipitor, Lyrica, Norvasc, Celebrex, ARV products

95%
Source evidence
“The Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise.”

Developed Markets segment

Developed Markets: operations primarily in North America and Europe; one of the largest providers of prescription medicines in the U.S.; key products include Lyrica, Lipitor, Creon, Breyna, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri

95%
Source evidence
“The Developed Markets segment comprises our operations primarily in North America and Europe. ... Significant products sold by the Developed Markets segment include Lyrica®, Lipitor®, Creon®, Breyna™, Influvac®, Wixela Inhub®, EpiPen® Auto-Injector, Fraxiparine®, and Yupelri®.”

Greater China segment

Greater China: mainland China, Taiwan, Hong Kong; predominantly branded LOE products; key products Lipitor, Norvasc, Viagra

95%
Source evidence
“The Greater China segment includes our operations in mainland China, Taiwan, and Hong Kong. The Viatris Greater China portfolio predominantly consists of branded LOE products.”

JANZ segment

JANZ: Japan, Australia, New Zealand; key products AMITIZA, EFFEXOR, Lipacreon, Lyrica, EpiPen; pipeline includes EFFEXOR (GAD), Nefecon, pitolisant

95%
Source evidence
“The JANZ segment consists of our operations in Japan, Australia and New Zealand. ... Significant products within the JANZ segment include AMITIZA®, EFFEXOR®, Lipacreon®, Lyrica®, and EpiPen® Auto-Injector.”

U.S. customer concentration among large firms

U.S. customer base is extensive but comprises a small number of very large firms due to pharmaceutical industry consolidation

90%
Source evidence
“While Viatris’ U.S. customer base is extensive, it comprises a small number of very large firms as the pharmaceutical industry has undergone tremendous change and consolidation.”

Channel types

Products reach patients via wholesalers/distributors, retailers, institutional pharmacies, mail-order/e-commerce pharmacies, and specialty pharmacies

92%
Source evidence
“Viatris’ products make their way to patients through a variety of intermediaries, or channels.”

Portfolio composition

Portfolio consists of generics (including complex products), globally recognized iconic brands, and an expanding portfolio of innovative medicines

95%
Source evidence
“Viatris’ portfolio consists of generics (including complex products), globally recognized iconic brands, and an expanding portfolio of innovative medicines.”

2025 total revenues

2025 total revenues of $14.30 billion despite divestitures and the Indore Impact

95%
Source evidence
“Viatris reported 2025 total revenues of $14.30 billion, despite the impact of divestitures and the Indore Impact”

Positioning and strategy

October 2025 Aculys Pharma acquisition

Acquired Aculys Pharma, gaining Japan rights to pitolisant and Spydia Nasal Spray in Japan/Asia-Pacific

94%
Source evidence
“including its October 2025 acquisition of Aculys Pharma, a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions primarily in Japan.”

Selatogrel and cenerimod development programs

Acquired Phase 3 programs selatogrel and cenerimod

92%
Source evidence
“our acquisition of the development programs for selatogrel and cenerimod, which are currently in Phase 3 development”

Aculys Pharma acquisition

Acquired Aculys Pharma with exclusive Japan rights to pitolisant and Spydia®

92%
Source evidence
“our acquisition of Aculys Pharma, including exclusive rights to pitolisant in Japan and Spydia® in Japan and certain other markets in the Asia-Pacific region”

Market types by country

Four pharmaceutical market types: prescription (U.S. brand, China, Turkey, Poland, Mexico), substitution (France, Italy, Spain, Portugal, Japan, Australia), tender (New Zealand, Sweden, South Africa, Germany), distribution (U.S. generics, U.K., Norway)

92%
Source evidence
“Examples of countries served by Viatris that are mainly prescription markets are the U.S. brand business, China, Turkey, Poland and Mexico.”

Recent divestitures 2022-2024

Divested biosimilars (Biocon Biologics), women's healthcare (Insud Pharma), API India (Matrix Pharma), OTC (Cooper Consumer Health), and Upjohn Distributor Markets rights

96%
Source evidence
“In July 2024, the Company completed the divestiture of its OTC Business to Cooper Consumer Health, a leading European OTC drug manufacturer and distributor.”

New product launches

New product launches are an important growth driver: iron sucrose injection, octreotide, pomalidomide, dapagliflozin, atorvastatin/ezetimibe, rivaroxaban, ferric carboxymaltose; Spydia Nasal Spray (Japan); sotagliflozin (UAE, Jan 2026)

93%
Source evidence
“New product launches are an important growth driver. Important recent launches include iron sucrose injection and octreotide acetate for injectable suspension in the U.S.”

Late-stage pipeline highlights

Pipeline: meloxicam MR-107A-02, contraceptive patch (PDUFA Jul 30 2026), phentolamine ophthalmic, selatogrel, cenerimod, potential first-to-market generics of Ozempic/Wegovy

93%
Source evidence
“on the potential to be first to market for its generics of Abilify Maintena®, Injectafer®, Ozempic®, and Wegovy™”

Enterprise-wide strategic review (EWSR) restructuring

EWSR restructuring: up to ~10% workforce reduction; $700-850M pre-tax charges; $600-700M expected savings over ~3 years

95%
Source evidence
“the Company expects to incur total pre-tax charges ranging between $700 million and $850 million”

Focus on complex and novel products

Increasingly focusing on limited-competition complex and novel products targeting unmet medical need with first-to-market emphasis; increasing R&D investment and growing inorganically via business development

93%
Source evidence
“expects to increasingly focus on limited-competition complex and novel products targeting areas of significant unmet medical need, all with a first-to-market emphasis”

Three strategic imperatives

Drive base business (launches, supply continuity, higher-margin generics, established brands); fuel innovative portfolio; modernize technology, data, talent

93%
Source evidence
“the Company also identified three strategic imperatives that will drive our future and position the Company for sustainable growth”

Innovative patent-protected asset expansion

Strategy to expand innovative, patent-protected asset portfolio, increasing R&D expense

90%
Source evidence
“As we look to accelerate our growth by building on the strength of our base business with an expanding portfolio of innovative, best-in-class, patent-protected assets, our related expenses have increased and will likely continue to increase.”

Risks, financing, and outlook

Significant indebtedness

Significant indebtedness with refinancing-rate risk; no guarantee of continued dividends or share repurchases

88%
Source evidence
“We have significant indebtedness, which could lead to adverse consequences or adversely affect our financial position and prevent us from fulfilling our obligations under such indebtedness”

Japan Amitiza generic entry risk

Generic entry for Amitiza 24 μg may occur in Japan in June 2026 depending on the outcome of patent litigation

90%
Source evidence
“generic entry for Amitiza® 24 μg may occur in Japan in June 2026 depending on the outcome of patent litigation.”

Indore facility FDA remediation

Remediation ongoing at Indore, India oral finished dose facility; in regular communication with the FDA

93%
Source evidence
“Viatris made substantial progress on its initial remediation activities at its oral finished dose manufacturing facility in Indore, India”

Extensive government regulation of pharmaceuticals

Products and manufacturing subject to rigorous, lengthy, costly regulatory approval and ongoing post-marketing review and inspection; failures/delays could adversely affect product revenue

90%
Source evidence
“Regulation by governmental authorities is a significant factor in the R&D, production, marketing, sales and distribution of pharmaceuticals.”

Hatch-Waxman 180-day exclusivity

180-day first-applicant generic exclusivity under Hatch-Waxman with forfeiture risk

88%
Source evidence
“the Hatch-Waxman Act provides for a period of 180 days of generic marketing exclusivity for a “first applicant””

Goodwill impairment in 2025

$2.94 billion goodwill impairment charge in 2025

98%
Source evidence
“including a goodwill impairment charge of $2.94 billion in 2025”

China VBP pricing pressure

China VBP policy (7th year, ~490 molecules) includes all major Viatris brands; hospital channel pricing/volume pressure expected to continue in 2026; company pivoted to retail pharmacy and e-commerce channels

95%
Source evidence
“The VBP policy for LOE molecules is now in its seventh year and includes approximately 490 molecules. All major Viatris brands are included in the VBP molecule lists.”

Loss of exclusivity for Amitiza in Japan

May lose market exclusivity for Amitiza® 24 μg in Japan in June 2026

95%
Source evidence
“we may lose market exclusivity for Amitiza® 24 μg in Japan in June 2026”

Manufacturing concentration and third-party API reliance

Limited manufacturing sites and third-party suppliers producing a substantial portion of API/products create operational risk

92%
Source evidence
“We have a limited number of manufacturing facilities and certain third-party suppliers produce a substantial portion of our API and products”

Generic competition in China

Strong generic-manufacturer competition in China causing price cuts and volume loss on some branded products

90%
Source evidence
“In China, for example, we face strong competition from certain generic manufacturers, which has resulted and may in the future result in price cuts and volume loss on some of Viatris’ branded products”

Pricing pressure and supply-chain consolidation

Pricing/reimbursement pressure from drug-pricing controls, social/government pressure and supply-chain consolidation

90%
Source evidence
“We have and may continue to experience pressure on the pricing of and reimbursements for certain of our products due to pricing controls, social or government pressure to lower the cost of drugs, and consolidation across the supply chain.”

Tariffs and trade restrictions

Tariffs and trade restrictions on territories where company, partners, suppliers or customers operate could materially harm results

90%
Source evidence
“The imposition of tariffs on, or other trade restrictions or domestic sourcing requirements in, the territories and countries where we, our partners, suppliers, or customers do business”

Patent cliffs and generic erosion

Loss of patent protection drives rapid generic erosion of sales

90%
Source evidence
“New generic market entrants generally cause continued price, margin, and sales erosion over the generic product life cycle.”

Tender systems and government price cuts

Government-imposed price reductions and tender systems for generics outside the U.S. pressure sales and profitability; generic-favoring initiatives may partially mitigate

90%
Source evidence
“Such measures, along with the tender systems discussed below, are likely to have a negative impact on sales and gross profit in these markets.”

Counterfeit and diverted product risk

Counterfeit, IP-infringing, diverted or stolen products threaten sales and reputation

88%
Source evidence
“unauthorized diversions of products or thefts of inventory at warehouses, plants, or while in-transit could result in improper storage or compromise product integrity”

Acquisition-related charges

Acquisitions may generate material charges (impairments, restructuring, contingent liabilities)

88%
Source evidence
“impairment of goodwill or intangible assets, including acquired IPR&D”

ARV competition in emerging markets

Increased competition and contracting markets for ARV products in emerging markets

85%
Source evidence
“In many emerging markets, we face increased competition and contracting markets for certain of our ARV products, primarily related to competing therapies.”

Geopolitical and international operations risk

Geopolitical instability and disasters in countries where company and suppliers operate

85%
Source evidence
“changes in U.S. agency procurement policies for pharmaceutical products manufactured in India or China”

Economic conditions and inflation risk

Inflation and macro volatility could reduce consumer/payer spending on pharmaceuticals

85%
Source evidence
“Current and changing economic conditions, including inflation, may adversely affect our industry, business, partners and suppliers.”

PBMs and market-structure competition

PBM contracting and pharmacy/purchaser consolidation may hurt product utilization

85%
Source evidence
“PBMs and other pharmaceutical manufacturers may utilize contracting strategies that could decrease utilization of or otherwise negatively impact our products”

Material exposure graph

US
Customer Exposure

U.S. customer base is a small number of very large consolidated firms; generic products contribute most to revenues and margins at launch and during market exclusivity, making timing of U.S. launches highly impactful.

Relevance 90·Dependency 80·Confidence 90
Source evidence
“While Viatris’ U.S. customer base is extensive, it comprises a small number of very large firms”
U.S. FDA
Regulatory Exposure

FDA remediation at Indore facility; 505(b)(2) NDAs with FDA target action dates; heavily regulated pharmaceutical industry

Relevance 90·Dependency 80·Confidence 92
Source evidence
“The Company has been in regular communication with the FDA during this process and will continue to work to ensure that the FDA is satisfied with the steps taken”
Healthcare (global pharmaceutical industry)
Competitive Exposure

Highly competitive, highly regulated global pharmaceutical industry: U.S. competition on innovation, FDA approval timing, supply chain, formulary placement and price; Europe competition on pricing, quality standards, service levels and portfolio; additional generic competition reduces volume and pricing.

Relevance 85·Dependency 80·Confidence 92
Source evidence
“The global pharmaceutical industry is a highly competitive and highly regulated industry.”
China
Regulatory Exposure

China's VBP policy covers ~490 molecules including all major Viatris brands, causing hospital channel pricing/volume pressure expected to continue in 2026; company re-balanced to retail pharmacy and e-commerce channels.

Relevance 85·Dependency 75·Confidence 92
Source evidence
“Additional pricing and volume pressure for pharmaceutical products sold in the hospital channel is expected to continue during 2026 and could negatively impact the Company’s results of operations.”
Viatris base business
Demand Driver

EWSR imperative to drive base business via successful launches, supply chain continuity, shifting generics toward higher-margin products, and strengthening established brands

Relevance 85·Dependency 70·Confidence 85
Source evidence
“By executing successful launches, focusing on supply chain continuity, evolving our generics portfolio over time towards more profitable, higher-margin products and strengthening our established brands portfolio.”
Active pharmaceutical ingredients (API)
Supplier Dependency

Third-party suppliers produce a substantial portion of API and products, creating supply-chain dependency; India API business divested to Matrix Pharma

Relevance 80·Dependency 75·Confidence 90
Source evidence
“certain third-party suppliers produce a substantial portion of our API and products, some of which require a highly exacting and complex manufacturing process.”
Retail/pharmacy, wholesalers, governments, institutions, physicians
Customer Exposure

Products reach patients through retail and pharmacy establishments, wholesalers, governments, institutions, physicians and other customers

Relevance 75·Dependency 65·Confidence 90
Source evidence
“serve patients in almost every corner of the globe through retail and pharmacy establishments, wholesalers, governments, institutions, physicians and other customers”
Tariffs and trade restrictions
Geopolitical Exposure

Tariffs, trade restrictions, domestic sourcing requirements and retaliation could materially affect operations and costs

Relevance 75·Dependency 60·Confidence 88
Source evidence
“The imposition of tariffs on, or other trade restrictions or domestic sourcing requirements in, the territories and countries where we, our partners, suppliers, or customers do business”
China
Competitive Exposure

Strong generic competition in China has caused and may cause price cuts and volume loss on Viatris branded products without patent/regulatory protection.

Relevance 75·Dependency 55·Confidence 90
Source evidence
“In China, for example, we face strong competition from certain generic manufacturers, which has resulted and may in the future result in price cuts and volume loss on some of Viatris’ branded products”
Japan
Demand Driver

Japan's National Health Insurance regulates pharmaceutical pricing; possible generic entry for Amitiza 24 μg in June 2026 pending patent litigation could cause substantial branded sales decline.

Relevance 70·Dependency 65·Confidence 88
Source evidence
“In Japan, the National Health Insurance regulates the pricing of pharmaceutical products to healthcare providers.”
Retail pharmacy and e-commerce channels (Greater China)
Revenue Exposure

In Greater China, Viatris expanded focus on retail pharmacy and e-commerce channels, where healthcare consumerism and increased spending power generated strong growth, partially offsetting hospital channel VBP losses.

Relevance 70·Dependency 60·Confidence 88
Source evidence
“The Company has re-balanced its business to expand its focus on the retail pharmacy and e-commerce channels while maintaining its presence in the hospital channel.”
Hatch-Waxman Act
Regulatory Exposure

First-applicant 180-day generic exclusivity under Paragraph IV certifications affects generic franchise economics, with forfeiture risk if approval timing lapses.

Relevance 70·Dependency 55·Confidence 88
Source evidence
“If we are unable to obtain approval or tentative approval within that time period, we may risk forfeiture of such marketing exclusivity.”
Geopolitical events
Competitive Exposure

International operations expose results to inflation, elections, geopolitical events including Middle East conflict and Russia-Ukraine war and related trade controls, sanctions, supply chain disruptions and staffing challenges.

Relevance 65·Dependency 55·Confidence 85
Source evidence
“geopolitical events, including the ongoing conflicts in the Middle East and between Russia and Ukraine and related trade controls, sanctions, supply chain disruptions and staffing challenges”
Key personnel retention
Cost Driver

Future success highly dependent on attracting and retaining key personnel; EWSR includes up to ~10% workforce reduction risk

Relevance 65·Dependency 55·Confidence 85
Source evidence
“Our future success is highly dependent on our ability to attract, motivate and retain key personnel.”
Pharmacy benefit managers (PBMs)
Competitive Exposure

PBM contracting strategies and consolidation of distribution outlets could decrease utilization of products.

Relevance 60·Dependency 50·Confidence 85
Source evidence
“PBMs and other pharmaceutical manufacturers may utilize contracting strategies that could decrease utilization of or otherwise negatively impact our products”
Japan
Revenue Exposure

Potential loss of market exclusivity for Amitiza® 24 μg in Japan in June 2026 creates revenue erosion exposure.

Relevance 60·Dependency 40·Confidence 95
Source evidence
“we may lose market exclusivity for Amitiza® 24 μg in Japan in June 2026”
Australia
Regulatory Exposure

Australian pharmaceutical pricing of reimbursed products is government-regulated under the PBS, funded via the Medicare levy and company/patient contributions; sales primarily through the wholesale system.

Relevance 55·Dependency 50·Confidence 85
Source evidence
“Pricing of reimbursed pharmaceutical products is regulated by the government and funded via the Medicare levy and through company and patient contributions.”
U.S. government funding for Emerging Markets products
Demand Driver

U.S. governmental agencies provide funding for certain products in the Emerging Markets region; any reduction in that funding is expected to negatively impact financial condition, results of operations or cash flows.

Relevance 55·Dependency 45·Confidence 85
Source evidence
“U.S. governmental agencies provide funding for certain products in our Emerging Markets region. We expect that any reduction in that funding will have a negative impact on our financial condition”
Inflation and macroeconomic volatility
Demand Driver

Inflation, sovereign debt risk and government spending cuts could reduce patient and payer spending on pharmaceuticals.

Relevance 55·Dependency 45·Confidence 85
Source evidence
“This has led, or could lead, to reduced consumer and customer spending, reduced or eliminated governmental or third-party payor coverage or reimbursement or reduced spending on healthcare”
India
Geopolitical Exposure

U.S. procurement policy changes for pharmaceuticals manufactured in India are a cited geopolitical/regulatory risk to the manufacturing-dependent supply chain.

Relevance 55·Dependency 45·Confidence 80
Source evidence
“changes in U.S. agency procurement policies for pharmaceutical products manufactured in India or China”
Geopolitical instability and supply disruption
Legal Exposure

Wars, pandemics, natural disasters, and political instability in countries where the company, partners, and suppliers operate could disrupt operations and demand.

Relevance 50·Dependency 40·Confidence 80
Source evidence
“local disturbances, the outbreak of highly contagious diseases or other health epidemics or pandemics, terrorist attacks, riots, social disruption, wars, or regional hostilities in the countries in which we or our partners and suppliers operate”
Full company information
Latest profile, trading, valuation, and identifier data stored for VTRS.
Share price
$18.67
Market cap
$21.44B
Exchange
NASDAQ
Currency
USD
CEO
Scott Andrew Smith
Employees
30,000
IPO date
17/03/1980
Beta
0.858
Last dividend
$0.00
Day range
$18.65 – $19.12
52-week range
$9.92 – $19.51
1-day performance
-1.92%
1-year performance
88.21%
Current drawdown (1Y)
-4.31%
CIK
0001792044
CUSIP
92556V106
ISIN
US92556V1061
Created
07/12/2025, 15:02:15
Last update
03/11/2026, 04:06:26

Track Viatris Inc. with an AI analyst

See which prediction-market events move VTRS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to VTRS from your Railway `news_articles` table.

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

Zacks Investment Research • STOCK • 19/05/2026, 14:41:09

Here's Why Viatris (VTRS) is a Strong Momentum Stock

Zacks Investment Research • STOCK • 18/05/2026, 12:50:16

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 12/05/2026, 18:00:56

Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)

Seeking Alpha • STOCK • 12/05/2026, 06:54:00

Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China

Zacks Investment Research • STOCK • 07/05/2026, 16:41:16

Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 07/05/2026, 16:21:18

Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings

Zacks Investment Research • STOCK • 07/05/2026, 12:31:33

Viatris (VTRS) Q1 Earnings and Revenues Surpass Estimates

Zacks Investment Research • STOCK • 07/05/2026, 11:55:51

Viatris Gears Up to Report Q1 Earnings: What's in the Cards?

Zacks Investment Research • STOCK • 05/05/2026, 16:20:17

Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

PRNewsWire • STOCK • 10/04/2026, 08:59:00

Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines Transcript

Seeking Alpha • STOCK • 25/03/2026, 20:15:57

Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up

Zacks Investment Research • STOCK • 26/02/2026, 13:46:31